Biologics/Biosimilars

(P-052) Evaluation the Pattern of Treatment in Inflammatory Bowel Disease: Before and After Approved Policy on Biologicals

(P-054) Validation Test for Algorithms to Identify Rheumatoid Arthritis Patients in the Tuscan Healthcare Administrative Databases

(P-100) Characterization of Real-world Data Sources to Support Observational Studies of Biologics, Including Biosimilars in Oncology

(P-124) Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID19 Pandemic in a Community Practice-based Network

(P-143) Prescribing Patterns of Lipegfilgrastim in EU: A Retrospective Study

(P-308) Penetration Rate of Anti-tnf Biosimilars in Hospitals in France: 5 Years Status

(P-377) Users of Biologics for Crohn’s Disease and Ulcerative Colitis in the Netherlands

(P-515) Factors Predictive of Treatment Success of Novel Disease-modifying Anti-rheumatic Drugs (DMARDS) in Patients with Inflammatory Arthritis

(P-533) PD-1 Immune Checkpoint Inhibitors and Serious Immune-related Adverse Events

(P-539) The Association Between Trajectories of Use of Systemic Agents and Depression in Patients with Psoriasis: A Sequence and Cluster Analysis

(P-635) Are Biologic Medicines Getting a FAERS Go? A Case Study of Rituximab and Pyoderma Gangrenosum (PG)